News >

Liver-Directed Therapy Shows Improvement in mCRC

Danielle Bucco
Published: Friday, Jan 05, 2018

Nancy E. Kemeny, MD

Nancy E. Kemeny, MD
Treating liver metastases in patients with metastatic colorectal cancer (CRC) remains a common and ongoing challenge. According to Nancy E. Kemeny, MD, approximately 70% of patients with metastatic CRC will develop liver metastases.

on Gastrointestinal Cancers, Kemeny, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed the combination of pump and systemic therapy as a liver-directed treatment option for patients with metastatic CRC.

OncLive: Please provide an overview of your presentation on liver-directed therapy for patients with metastatic CRC.

Kemeny: I discussed direct treatment to the liver. Even though we have new and better drugs for the treatment of CRC, we still have patients who die from metastatic disease. The liver is the main area of metastatic disease. About 70% of patients with metastatic disease will have liver metastases, and some people will have only liver metastases. Therefore, one can think about directing chemotherapy into the liver to help those patients. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication